| Literature DB >> 34525872 |
Hiroyuki Ogasawara1, Akiko Inagaki2, Ibrahim Fathi2, Takehiro Imura2, Hiroki Yamana1, Yoshikatsu Saitoh1, Muneyuki Matsumura1, Kengo Fukuoka1, Shigehito Miyagi1, Yasuhiro Nakamura3, Kazuo Ohashi4, Michiaki Unno1, Takashi Kamei1, Masafumi Goto1,2.
Abstract
Intraportal injection is regarded as the current standard procedure of hepatocyte transplantation (HTx). In islet transplantation, which shares many aspects with HTx, recent studies have clarified that instant blood-mediated inflammatory reaction (IBMIR), characterized by strong innate immune responses, can cause poor engraftment, so other transplant sites to avoid such a reaction have been established. Although IBMIR was reported to occur in HTx, few reports have evaluated alternative transplant sites for HTx. In this study, we sought to determine the optimum transplant site for HTx. Rat hepatocytes (1.0 × 107) were transplanted at the 9 transplant sites (intraportal (IPO), intrasplenic (IS), liver parenchyma, subcutaneous, intraperitoneal, renal subcapsular, muscle, inguinal subcutaneous white adipose tissue, and omentum) of analbuminemic rats. The serum albumin levels, immunohistochemical staining (albumin, TUNEL, and BrdU), and in vivo imaging of the grafts were evaluated. The serum albumin levels of the IPO group were significantly higher than those of the other groups (p < .0001). The BrdU-positive hepatocyte ratio of liver in the IS group (0.9% ± 0.2%) was comparable to that of the IPO group (0.9% ± 0.3%) and tended to be higher than that of the spleen in the IS group (0.5% ± 0.1%, p = .16). Considering the in vivo imaging evaluation and the influence of splenectomy, the graft function in the IS group may be almost entirely achieved by hepatocytes that have migrated to the liver. The present study clearly showed that the intraportal injection procedure is more efficient than other procedures for performing HTx.Entities:
Keywords: IVIS; hepatocyte transplantation; portal; spleen; transplant site
Mesh:
Year: 2021 PMID: 34525872 PMCID: PMC8450989 DOI: 10.1177/09636897211040012
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064